NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Get Started

$60.50 +0.72 (+1.20 %)

(As of 03/19/2019 04:00 PM ET)

Previous Close$59.78

Today's Range$59.96 - $60.87

52-Week Range$56.58 - $91.35

Volume1.04 million shs

Average Volume2.05 million shs

Market Capitalization$9.16 billion

P/E Ratio14.65

Dividend YieldN/A

Beta0.88

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical & hospital equipment

Sub-IndustryHealth Care Distributors

SectorMedical

Current SymbolNASDAQ:HSIC

Previous Symbol

CUSIP80640710

CIK1000228

Webwww.henryschein.com

Phone631-843-5500

Debt

Debt-to-Equity Ratio0.28

Current Ratio1.30

Quick Ratio0.68

Price-To-Earnings

Trailing P/E Ratio14.65

Forward P/E Ratio17.59

P/E Growth2.2

Sales & Book Value

Annual Sales$13.20 billion

Price / Sales0.69

Cash Flow$5.6437 per share

Price / Cash Flow10.72

Book Value$23.23 per share

Price / Book2.60

Profitability

EPS (Most Recent Fiscal Year)$4.13

Net Income$535.88 million

Net Margins4.06%

Return on Equity19.86%

Return on Assets7.79%

Miscellaneous

Employees18,000

Outstanding Shares151,404,000

Market Cap$9.16 billion

Next Earnings Date5/14/2019 (Estimated)

OptionableOptionable

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein announced that its board has authorized a stock buyback plan on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 3.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings data on Wednesday, February, 20th. The company reported $1.12 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.11 by $0.01. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.46 billion. Henry Schein had a net margin of 4.06% and a return on equity of 19.86%. Henry Schein's revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.97 earnings per share. View Henry Schein's Earnings History.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Henry Schein.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein issued an update on its FY19 earnings guidance on Wednesday, February, 20th. The company provided EPS guidance of $3.38-3.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.75. Henry Schein also updated its FY 2019 guidance to $3.38-3.46 EPS.

What price target have analysts set for HSIC?

16 Wall Street analysts have issued 1-year price targets for Henry Schein's shares. Their forecasts range from $62.00 to $102.00. On average, they anticipate Henry Schein's share price to reach $78.5707 in the next year. This suggests a possible upside of 29.9% from the stock's current price. View Analyst Price Targets for Henry Schein.

What is the consensus analysts' recommendation for Henry Schein?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 4 sell ratings, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

What are Wall Street analysts saying about Henry Schein stock?

Here are some recent quotes from research analysts about Henry Schein stock:

1. According to Zacks Investment Research, "Henry Schein exited the fourth quarter of 2018 on a mixed note. We are disappointed with the year-over-year deterioration in gross and operating margin due to higher expenses. Pricing pressure, tough competition and adverse currency movements are other concerns. Nonetheless, Henry Schein saw solid performance by the global Medical and Technology and Value-added Services businesses. The company's strong share gain in the North American market raises optimism. Moreover, management seems to be upbeat about the creation of the Henry Schein One dental technology business and the completion of the spin-off of its animal health business into Covetrus. We are looking forward to Henry Schein’s new agreement to buy a dental practice management solutions company, Kopfwerk. In the past six months, Henry Schein has underperformed the S&P market." (2/26/2019)
2. Barrington Research analysts commented, "We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur around year end. In addition, the guidance does not factor in any future M&A activity." (11/8/2018)

Has Henry Schein been receiving favorable news coverage?

Press coverage about HSIC stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Henry Schein earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the stock's share price in the near future.

Are investors shorting Henry Schein?

Henry Schein saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 15,377,889 shares, an increase of 13.2% from the January 31st total of 13,581,449 shares. Based on an average trading volume of 2,595,400 shares, the short-interest ratio is currently 5.9 days. Approximately 10.2% of the shares of the stock are short sold. View Henry Schein's Current Options Chain.

Who are some of Henry Schein's key competitors?

Some companies that are related to Henry Schein include Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), FRESENIUS SE &/S (FSNUY), Alexion Pharmaceuticals (ALXN), ESSILOR INTL S/S (ESLOY), Zimmer Biomet (ZBH), Centene (CNC), Eisai (ESALY), Fresenius Medical Care AG & Co. (FMS), TERUMO CORP/ADR (TRUMY), McKesson (MCK), LONZA GRP AG/ADR (LZAGY), Fresenius Medical Care AG & Co. KGaA (FME) and COLOPLAST A/S/ADR (CLPBY).

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Walt Disney (DIS), salesforce.com (CRM), Amgen (AMGN), AT&T (T), Celgene (CELG), Bank of America (BAC) and AbbVie (ABBV).

Who are Henry Schein's key executives?

Henry Schein's management team includes the folowing people:

Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 69)
Mr. James P. Breslawski, Vice Chairman & Pres (Age 65)
Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 62)
Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 66)
Mr. Ronald South, Chief Accounting Officer & VP of Corp. Fin.

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Longview Partners Guernsey LTD (8.67%), BlackRock Inc. (7.29%), FMR LLC (4.63%), Atlanta Capital Management Co. L L C (4.10%), Alecta Pensionsforsakring Omsesidigt (2.87%) and Mackenzie Financial Corp (2.65%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Gerald A Benjamin, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

Which major investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., FMR LLC, Congress Asset Management Co. MA, Park West Asset Management LLC, Alecta Pensionsforsakring Omsesidigt, Mackenzie Financial Corp, Longview Partners Guernsey LTD and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

Which major investors are buying Henry Schein stock?

HSIC stock was bought by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, Norges Bank, BlackRock Inc., Nordea Investment Management AB, Retirement Systems of Alabama, State of Tennessee Treasury Department, California Public Employees Retirement System and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Henry Schein.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $60.50.

How big of a company is Henry Schein?

Henry Schein has a market capitalization of $9.16 billion and generates $13.20 billion in revenue each year. The company earns $535.88 million in net income (profit) each year or $4.13 on an earnings per share basis. Henry Schein employs 18,000 workers across the globe.

What is Henry Schein's official website?

The official website for Henry Schein is http://www.henryschein.com.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]

MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		271 (Vote Outperform)
Underperform Votes:		480 (Vote Underperform)
Total Votes:		751

MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 3/19/2019 by MarketBeat.com Staff